BlackRock Inc. raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 340,938 shares of the biopharmaceutical company’s stock after acquiring an additional 37,820 shares during the period. BlackRock Inc. owned about 2.27% of Celldex Therapeutics worth $914,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. HighTower Advisors LLC acquired a new position in shares of Celldex Therapeutics in the 2nd quarter worth approximately $31,000. Wedbush Securities Inc. acquired a new position in shares of Celldex Therapeutics in the 2nd quarter worth approximately $36,000. Acadian Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 82.0% in the 2nd quarter. Acadian Asset Management LLC now owns 267,557 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 120,519 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Celldex Therapeutics by 67.4% in the 2nd quarter. Renaissance Technologies LLC now owns 912,285 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 367,179 shares in the last quarter. 24.85% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Wednesday, October 9th. ValuEngine raised Celldex Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th.
Shares of CLDX opened at $2.35 on Tuesday. Celldex Therapeutics, Inc. has a 1 year low of $2.01 and a 1 year high of $11.63. The company has a current ratio of 7.33, a quick ratio of 7.33 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $2.29 and a 200-day simple moving average of $2.68. The stock has a market cap of $35.29 million, a PE ratio of -0.34 and a beta of 3.51.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.17) by $0.33. Celldex Therapeutics had a negative return on equity of 42.93% and a negative net margin of 942.48%. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period in the prior year, the firm posted ($1.65) EPS. On average, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -3.98 EPS for the current fiscal year.
About Celldex Therapeutics
Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
Recommended Story: Using other technical indicators with support levels
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.